Experiments were performed using murine BMDMs. (A) Intra‐phagosomal proteolysis in WT,
Nfkb1[SSAA] (
Nfkb1
SSAA/SSAA), and
Nfkb1[SSAA]/
Tpl2[D270A] BMDMs were monitored as in Fig
1B (
n = 4 wells). (B) Intra‐phagosomal acidification in WT,
Nfkb1[SSAA], and
Nfkb1[SSAA]/
Tpl2[D270A] BMDMs was monitored as in Fig
1C (
n = 4 wells). (C) Cell extracts from LPS‐stimulated
Nfkb1[SSAA] and
Nfkb1[SSAA]/
Tpl2[D270A] BMDMs were immunoblotted for the indicated antigens. (D) Intra‐phagosomal proteolysis in WT and inhibitor‐treated BMDMs (
n = 4 wells) was monitored as in Fig
1B. BMDMs were pre‐treated with 0.1 μM PD0325901 (10 min) to inhibit MEK1, pre‐treated with 1 μM VX‐745 (1 h) to inhibit p38α, and pre‐treated with 10 μM C34 (1 h) to inhibit TPL‐2. (E). Intra‐phagosomal acidification in WT and inhibitor‐treated BMDMs (see (D) for conditions) was assayed as in Fig
1C (
n = 4 wells). (F) Cell extracts from LPS‐stimulated, inhibitor‐treated WT, and
Tpl2[D270A] BMDMs were immunoblotted for the indicated antigens. 1 μM bafilomycin A1 was added to inhibit V‐ATPases.